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Brugada syndrome is known to be a life-threatening disease
provoking lethal arrhythmias such as ventricular tachy-
cardia/ventricular ﬁbrillation (VF), but non–implantable
cardioverter-deﬁbrillator (ICD) treatment strategy remains
a topic of discussion.1 Substrate-based catheter ablation
of Brugada syndrome has been reported to be effective,2,3
but much is still unknown, for example, the relationship
between local abnormal endocardial potentials and ablation
results.
Case report
A 37-year-old man was referred to our hospital after
resuscitation from VF due to Brugada syndrome and an
ICD was implanted for secondary prevention. A second VF
attack occurred 8 months later, and oral bepridil (100 mg/d; a
drug shown to have some success in reducing electrical
storms in patients with Brugada syndrome4–6) was initiated.
After a year and half of remission, there was a recurrence of
VF, and over the next 6 months, there were 9 appropriate
ICD shocks (all for VF). Both type 1 and type 2 Brugada
electrocardiographic (ECG) patterns were observed with
ﬂuctuating amplitude at the time of ICD implantation, but
the coved-type ECG became constant as the VF attacks
increased. An increased dose of bepridil (200 mg/d) and
cilostazol (200 mg/d) failed to control VF and VF progressed
to electrical storms (maximum 3 times in a day). At that
point, the decision was made to perform catheter ablation for
the arrhythmia.
Premature ventricular contraction (PVC) triggering VF had
never been observed, and substrate ablation in the endocardial
right ventricular outﬂow tract (RVOT) was attempted withKEYWORDS Catheter ablation; Brugada syndrome; ICD
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).preparations for backup epicardial ablation, and the subxi-
phoid area was draped in a sterile fashion. CARTO 3
(BiosenseWebster, Diamond Bar, CA) mapping in the RVOT
showed low-voltage areas (o1.5 mV with bipolar mapping)
beneath the pulmonary artery valve circumferentially, and
also in the lower anterior aspect, with irregularly shaped
extensions to the lateral and septal areas. Fractionated or
delayed potentials were observed mostly within these low-
voltage areas including the posterior area, all of which were
targeted for ablation (Figure 1). A ThermoCool SF (Biosense
Webster, Diamond Bar, CA) catheter was used, and radio-
frequency (RF) energy within the range of 30–35 W was
delivered. During the procedure, VF occurred 5 times. Of
these, 4 were provoked during catheter mapping and the ﬁfth
occurred during RF application at an RVOT anterior site.
Circumferential and zonal ablation was performed in the
RVOT with a total application count of 59 times (55 minutes)
and a total energy of 96,186 J. The 12-lead ECG changed
gradually as the ablation procedure progressed. After the ﬁnal
RF application, the coved-type morphology in lead V1 had
disappeared and ST-segment elevation in lead V2 had
diminished (Figure 2). The last VF occurred in the middle
of the procedure, after which no further VF was observed. We
ended the procedure when all the fractionated or delayed
potentials were ablated in a manner similar to when substrate
ablation is conducted in the epicardium,2 but an additional
drug stress test was not performed because of the prolonged
procedure time and the high frequency of necessary deﬁb-
rillation shocks during the procedure.
The patient was discharged 2 days after the ablation procedure
without complication. The minimum ST level was observed 6
weeks after the procedure (Figure 3). Cilostazol (200 mg/d) was
used just after the ablation procedure, but was tapered and
discontinued 2 months after the procedure. During the 6-month
observation period after the procedure, an appropriate ICD shock
for VF was experienced once within 5 months, and a subsequent
disopyramide stress test for the evaluation of the remaining
arrhythmogenicity proved positive with the appearance of the
coved-type ECG patterns in lead V1. However, no further VFpen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2016.06.007
KEY TEACHING POINTS
 We recorded fractionated and/or delayed
potentials by contact bipolar mapping of the
endocardium in a patient with Brugada syndrome–
induced ventricular ﬁbrillation storms. Most of
those potentials were observed within low-voltage
areas in various right ventricular outﬂow tract
regions.
 Catheter ablation targeting these potentials
resulted in the normalization of the Brugada
electrocardiographic pattern and almost
completely suppressed ventricular ﬁbrillation
storms.
 This endocardial ablation technique may not work
for all patients with Brugada syndrome.
Identiﬁcation of remaining arrhythmogenicity from
the endocardium needs further exploration.
429Hayashi et al Endocardial Ablation for Brugada Syndromestorms have been observed since the ablation procedure up to the
present time.Discussion
For 1 particular case, we showed the effectiveness of
endocardial-only ablation in preventing Brugada syn-
drome–induced VF storms with debilitating ICD shocks in
the antiarrhythmic drug–free state. However, recurrence ofFigure 1 A: CARTO mapping in the endocardial right ventricular outﬂow tract
irregularly shaped extensions mostly in the anterior surface, but with some to the la
Fractionated and delayed potentials were observed mostly within the low-voltage
AP ¼ anterior-posterior view; d ¼ distal; p ¼ proximal; PA ¼ posterior-anteriorVF once and the appearance of the Brugada ECG pattern on
pharmacological challenge during follow-up show the lim-
itations of our method in curing the underlying substrate of
the arrhythmia.Endocardial substrate ablation
In our case, PVCs triggering VF had never been detected before
the ablation procedure,7,8 so a substrate-modifying ablation
strategy was selected. Nademanee et al2 performed an initial
substrate-based catheter ablation of Brugada syndrome in the
epicardium. Sunsaneewitayakul et al3 reported endocardium
substrate ablation by identifying the late activation zones (LAZs)
in the RVOT using noncontact mapping (EnSite 3000, St. Jude
Medical, Minneapolis, MN), and the LAZs were targeted as
ablation sites. In our case, endocardial ablation was performed
targeting the fractionated and/or delayed potentials recorded by
conventional 3-dimensional contact mapping. In the literature, it
has been reported that these local abnormal potentials could be
detected in the endocardial site in the RVOT,9 but ablation
targeting these potentials is rarely adopted, probably because
these potentials are not always detected in patients with Brugada
syndrome, and its efﬁcacy is still uncertain. Although Shah et al10
reported a case of endocardial ablation with Brugada syndrome,
target locations in the RVOT were determined on the basis of
pace mapping using the clinical PVC as reference, and local
abnormal potentials were not mentioned. Our case demonstrated
the potential effectiveness of local electrogram-guided endocar-
dial-only ablation with conventional 3-dimensional contact
mapping in Brugada syndrome for preventing VF storms.showed low-voltage areas beneath the pulmonary artery valve, with discrete
teral and septal sides. B: Electrograms from areas marked a to c in panel A.
area, all of which were targeted as ablation sites. ABL ¼ ablation catheter;
view; RV ¼ right ventricle; SPT ¼ sinus of pulmonary trunk.
Figure 2 All the delayed and fractionated potentials around the right ventricular outﬂow tract were targeted and ablated. Red tags show ablation points.
Application power was limited to 30W except for some septal sites where it was 35W, and an SL0 sheath was used tomaintain ﬁrm contact (A). Typical coved-type
electrocardiogram displayed at the beginning of the procedure (Before). ST-segment elevation gradually diminished as ablation proceeded Radio frequency catheter
ablation (RFCA 24). We ended the procedure with the disappearance of the coved-type electrocardiographic pattern, the improvement of ST-segment elevation in
lead V2, and the cessation of ventricular ﬁbrillation occurrences (Final Application (59)) (B). AP ¼ anterior-posterior view; PA ¼ posterior-anterior view.
Heart Rhythm Case Reports, Vol 2, No 5, September 2016430Endocardial fractionated potentials were detected not only
in the anterior aspect of the RVOT but also in the lateral,
septal, and posterior aspects in our case. These expanded
abnormal potentials in the RVOT may have a relationship to
the LAZ, because LAZs were also present in various
locations of the RVOT, and the existence of fractionated
potentials inside the LAZ has been reported in patients with
frequent VF by Sunsaneewitayakul et al.3
Epicardial arrhythmogenic substrate
Epicardial mapping was not performed in this case,
because sufﬁcient effect was achieved by the endocardial
approach alone in this subemergent situation. As a result, the
relationship between epicardial arrhythmogenicity and the
endocardial local abnormal potentials was not examined inFigure 3 ST level showed changes with daily variance over the 2 days after the ab
days after the procedure. Minimum ST level was observed 42 days after the procedu
half year of follow-up.this procedure. In our case, most of the delayed potentials
were observed in or near the low-voltage area. This is similar
to the distribution of delayed potentials in epicardial sites as
previously reported.2 There remains a possibility that endo-
cardial fractionated and/or delayed potential may reﬂect the
far-ﬁeld potential of the epicardial abnormal potentials and
that the ablation lesion from the endocardium might have
affected the arrhythmogenic sites in the epicardium. In this
regard, endocardial ablation in Brugada syndrome may
require the formation of transmural lesions, such as those
performed with the Thermocool SF catheter with support of
the SL0 sheath (St. Jude Medical Minneapolis, MN). Thick-
ness of the RVOT wall is estimated to be approximately
3–6 mm,11 and this anatomical variation may have an impact
on effectiveness in endocardial-only ablation.11lation procedure until discharge. Antiarrhythmic drugs were discontinued 14
re. The coved-type electrocardiographic pattern was not observed during the
431Hayashi et al Endocardial Ablation for Brugada SyndromeEnd point of the ablation procedure
We successfully met our end point of ablating all fractio-
nated and delayed potentials, noted the near normalization of
the Brugada ECG pattern and the disappearance of VF
during the procedure. Within a half year of the procedure, VF
recurred once in an antiarrhythmic drug–free state, and a
subsequent disopyramide stress test produced the coved-type
Brugada ECG pattern. These ﬁndings indicate that arrhyth-
mogenicity of Brugada syndrome in this patient was not fully
eradicated. This might be a limitation of endocardial-only
ablation in that the remaining arrhythmogenic substrate in
the epicardium could not be detected from the endocardium.
That said, endocardial ablation has an advantage over
epicardial-side ablation, which can cause severe complica-
tions.12 The unipolar voltage map (o5.5 mV) showed a more
extended low-voltage area in the RVOT than did the bipolar
voltage map, and this might be related to the remaining
arrhythmogenic substrate.13
We will consider performing epicardial ablation on this
patient, should he have a recurrent increase in VF episodes as
we follow him up.References
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